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Abstract: 
 
 
Frick, Morin Mae (M.S., Chemistry) 
 
 
 
The Synthesis of Unnatural Morphine Derivatives as Glial Activation Inhibitors and The 
Synthesis of Corticosterone-Glucuornide 
 
 
 
Thesis directed by Professor Tarek H. Sammakia 
 
 
 
 A novel, non-neuronal mechanism to explain the development of opioid tolerance and 
dependance has been described.  This mechanism involves the activation of spinal cord glia.  
Glia are important contributors to the creation of enhanced pain states via the release of 
neuroexcitatory and proinflammatory substances.  Data suggest that glia also release 
neuroexcitatory substances in response to morphine, thereby opposing its effects.  Inhibiting glial 
activation could therefore increase the clinical utility of analgesic drugs.  The synthesis of 
advanced intermediates for the development of a series of novel morphinan-like structures that 
are potential glial activation inhibitors will be discussed.  A Grewe-type cyclization of N-formyl 
compounds was the key reaction in two synthetic sequences to produce these intermediates in 
racemic form. 
 
 Morphine-3-glucuronide (M3G) is a major morphine metabolite detected in the 
cerebrospinal fluid of humans receiving systemic morphine.  M3G is known to induce pain by an 
unknown mechanism.  It has little to no affinity for opioid receptors and its pain-enhancing 
  
iv 
effects have been proposed to significantly and progressively oppose morphine analgesia.  
Recent work has shown it does so via transmembrane receptors on glial cells.  It has been known 
for some time that corticosterone (the rat version of human adrenal cortisol) displays an intense 
immunosuppressive effect at the time of delivery; however, recent work has shown that it 
produces dramatic glial and immune activation and a pro-inflammatory response later in time.  
Corticoserone is glucuronidated in its metabolic pathway.  Corticosterone-glucuronide (CortG) 
was synthesized to test whether the glucuronidation is the cause of the eventual pro-
inflammatory effects of corticosterone.  CortG was prepared by a direct coupling of a glucuronic 
acid imidate donor and corticosterone in the presence of borontrifuoride etherate.   
  
v 
Contents 
 
 
 
Abstract                                                                                                                                           iii 
 
List of Schemes                                                                                                                               vi 
 
 
 
 
The Synthesis of Unnatural Morphine Derivatives as Glial Activation Inhibitors 
 
 
1.1  Synthetic Strategies for the Preparation of Novel Morphinan-like Compounds                      5 
 
1.2 Synthetic Preparation of the Aromatic Unsubstituted Compounds                                           9 
 
1.3  Future Directions:  Asymmetric Transfer Hydrogenation, a Route to the (+)-Isomers          11 
 
 
Chapter Two:  The Synthesis of Corticosterone-glucuronide 
 
 
2.1 Synthetic Route to CortG                                                                                                        13 
 
 
Chapter Three:  Experimental Methods and Characterization                                                        
 
 
3.1 Procedures and Characterization of Compounds                                                                     15 
 
 
 
References                                                                                                                                      40 
 
  
vi 
List of Schemes 
 
Scheme 01  Stuctures of (-)-Morphine, (+)-Naloxone, and desired analogues                               5 
 
Scheme 02 Grewe cyclization of (±)-4 provided the undesired compound 6 as the major isomer 6 
Scheme 03 Synthetic route to compound (±)-2a                                                                             7 
Scheme 04 Synthesis of (±)-19                                                                                                        8 
 
Scheme 05 Glucronidation of morphine occurs in the liver via the enzyme UDP-glucoronosyl                
 
                   transferase (UGT)                                                                                                       10 
 
Scheme 06 Synthetic route to compounds (±)-3a-c                                                                       11 
 
Scheme 07 Asymmetric transfer hydrogenation of cyclic imines 14 and 24 catalyzed by a chiral  
 
                   Ru (II) complex                                                                                                           12 
 
Scheme 08 Synthesis of CortG 36                                                                                                 14 
 
 
 
  
1 
CHAPTER ONE: 
 
THE SYNTHESIS OF UNNATURAL MORPHINE DERIVATIVES AS GLIAL  
 
ACTIVATION INHIBITORS 
 
 Chronic pain affects more than 70 million Americans, which makes it more 
widespread than heart disease, cancer, and diabetes combined.1  Unfortunately, it frequently is 
inadequately treated leading to enormous social costs in the form of lost productivity, needless 
suffering, and excessive healthcare expenditures.1
 Important areas of research that are needed to help with the problem of opioid 
analgesic abuse include the identification of clinical practices that minimize the risks of 
addiction and mistreatment.  New understanding of the mechanism of pain sensation and the 
mechanism of action of opioid analgesics is providing new approaches to pain management.  
Historically, researchers have focused primarily on neuronal mechanisms of pain and analgesia 
while ignoring other potentially powerful modulators of nociception.  Further, it has been 
  Because pain is regarded as a significant 
public health issue, the search for new strategies to treat pain, acute or chronic, continues to 
grow.  Today, opioid pharmacotherapies constitute a significant component of many pain 
management plans.1  While opioids are potent analgesics, they have severe side effects including 
addiction, tolerance and abuse.  The abuse of and addiction to opioid analgesics is a major issue 
that leaves doctors and patients reluctant to treat pain with these agents to the fullest extent.2, 3 
                                                 
1 Hay, J., White, J., Bocher, F., Somogyi, A., Semple, T., Rounsefell, B.  The Journal of Pain.     
2009, 3, 316 – 322. 
2 Compton, W. M., Volkow, N. D.  Drug Alcohol Depend.  2006, 81,     103. 
3 Manchikanti, L.  Pain Physician  2006, 9, 287. 
  
2 
believed that both the detrimental and beneficial actions of opioids are mediated via potentially 
inseparable mechanisms reliant only on neuronal opioid receptors.4
 Recent experimental data has implicated glia (astrocytes and microglia) as 
important mediators of pain.  For many years glial cells were overlooked in pain research 
because, traditionally, they were viewed only as a support system for neurons and as having an 
important role in maintaining central nervous system homeostasis.4  Today, however, glia are 
known to have a well-established role in initiating and maintaining increased pain states in 
response to peripheral nerve injury.  More recently, several laboratories have documented that 
glia can powerfully modulate the analgesic actions of chronically administered opioids. 
 
5,6,7,8
  The earliest evidence of the role of glial cells in pain regulation was an 
associative link between glial activation and neuropathic pain published in 1994.
 
Based on such studies, the pharmacological targeting of glia, rather than solely neurons, may 
provide more effective pain control and enhanced efficacy of opioids.   
9
                                                 
4 Watkins, L., Hutchinson, M.  The Scientific World Journal.  2007, 7, 1 – 14. 
  This study 
reported the interesting observation that drugs which blocked neuropathic pain also decreased 
glial activation.  More recently, it has been reported that when glial cells are activated, they 
produce and release a variety of neuroexcitatory substances including reactive oxygen species, 
5 Johnston, I., Milligan, E., Weiseler-Frank, M., Zapata, V., Vampisi, J., Lnger, S. Martin, D., 
Green, P., Fleshner, M., Leinwant, L., mier, S., Watkins, L.  J. Neurosci.  2004, 24, 7353 
- 7365.  
6 Raghavendra, V., Tanga, F., DeLeo, J.  Neuropsychopharmacology.  2004, 29, 327 – 334. 
7 Raghavendra, V., Tanga, F., Rutkowski, M., DeLeo, J.  Pain.  2003, 104, 655 – 664. 
8 Song, P., Zhao, Z.  Neurosci. Res. 2001, 39, 281 – 286. 
9 Garrison, C. J., Dougherty, P., Carlton, S..  Exp. Neurol. 1994, 129, 237. 
10 Watkins, L. R., Milligan, E. D., Maier, S. F.  Adv. Exp. Med. Biol. 2003, 521, 1. 
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nitric oxide, prostaglandins, excitatory amino acids, and proinflammatory cytokines.10, 11
 Among the most important of these are the toll-like receptors (TLRs), more 
importantly, TLR4.
  Indeed, 
glial activation and subsequent release of proinflammatory mediators are now implicated in 
initiating and maintaining enhanced pain states.10   Several of these cytokine mediators and the 
receptor-mediated events that they initiate, have been well characterized.    
12, 13
 Given these considerations, the development of a glial cell activation/TLR4 
antagonist could be quite useful.  Professor Linda Watkins and her group at the Department of 
Psychology and the Center for Neuroscience at the University of Colorado at Boulder sought a 
blood brain barrier permeable, small molecule class of compounds that could block TLR4.  Their 
  The TLRs are a family of transmembrane proteins that recognize a 
diverse range of chemical space occupied by exogenous and endogenous substances that are 
considered to function as danger signals, and induce activation of the innate immune system 
aimed at defending the survival of the host.  TLR4 is especially intriguing with respect to glial 
activation.  It has been extensively characterized in that it is the toll-like receptor that recognizes 
LPS (the lipopolysaccharide of gram-negative bacteria such as E. coli and Salmonella) and other 
endogenous danger signals released by damaged, dying, and dead neurons and other cells.  It is 
clear that endogenous danger signals created as a result of nerve injury can cause chronic 
activation of glia via TLR4, and thereby establish a drive to maintain neuropathic pain.4  Thus, 
targeting glia, specifically at their TLRs, may have potential clinical utility. 
                                                 
11 Watkins, L. R., Milligan, E. D., Maier, S. F.  Trends Neurosci. 2001, 24, 450-455. 
12 Tanga, F., Nutile-McMenemy, M., DeLeo, J.  Proc. Natl. Acad. Scie. U. S. A.  2005, 102, 5856 
– 5861. 
13 Kim, D., Kim, M., Cho, I., Kim, M., Lee, S., Jo, E., Choi, S., Park, K., Kim, J., Akira, S., Na, 
H., Oh, S., Lee, S.  J. Biol. Chem. 2007, J. Biol. Chem. 2007, 282, 14975 – 14983. 
  
4 
attention was drawn to the work of Hong et al.14
 The Watkins group hypothesized that naloxone could bind to TLRs in addition to 
their well-known binding to classical opioid receptors.  To test this, they studied the effects of 
(+)-naloxone on LPS-induced activation of TLR4; and to their delight, (+)-naloxone was 
successful in antagonizing TLR4 activation.4   These data not only demonstrate novel receptor 
antagonistic action of (+)-naloxone, but reinforce the critical role of TLR4 receptors on glia in 
neuropathic pain.   
, 15, 16 and Lu17 et al. which demonstrated the 
blockade of LPS activity by the opioid receptor antagonist naloxone.  More importantly, it was 
documented that naloxone blocked microglial activation by LPS.  Interestingly, the Hong group 
found that the actions of naloxone on LPS-induced microglial activation were not mediated by 
classical neuronal opioid receptors because both the opioid active (-)-isomer and the opioid 
inactive (+)-isomer of naloxone exerted identical inhibitory effects.15  The observation that the 
(+)-isomer inhibited LPS-induced microglial activation was significant for it strongly suggested 
that naloxone must be acting through some receptor other than the classical opioid receptor, 
which only binds the (-)-isomer.   
The ground breaking discovery that opioid agonists activate TLR4 and an opioid 
antagonist would nonstereoselectively block TLR4 activation, suggests that the TLRs may lie at 
the intersection between neuropathic pain and opioid-induced glial activation.  Thus the exciting 
potential exists that unnatural enantiomers of opioids may be uniquely positioned to suppress 
opioid induced glial activation, and yet not compromise the pain-suppressive effects of opioid 
                                                 
14 Chang, R., Hong, J. S.  J. Brain Res.  2000, 854, 224. 
15 Liu, B., Du, L. Hong, J. S.  J. Pharmacol. Exp Ther.  2000, 293, 607. 
16 Liu, B., Du, L., Hong, J.  J. Pharmacol. Exp. Ther.  2000, 295, 125. 
17 Lu, X., Bing, G., Hagg, T.  Neuroscience 2000, 97, 285. 
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agonists on neurons.  Therefore, the aim of our research is to synthesize a novel class of 
compounds, 2a-c, 3a-c, similar in structure to (+)-naloxone (1) and study their ability to suppress 
opioid-induced glial activation (Scheme 01).   
 
Scheme 01.  Structures of (-)-Morphine, (+)-Naloxone, and desired analogues. 
 
1.1 SYNTHETIC STRATEGIES FOR THE PREPARATION OF NOVEL MORPHINAN-
LIKE COMPOUNDS 
 Our strategy for the synthesis of our desired analogs takes advantage of the 
Grewe cyclization of 1-benzyl-hexahydroisoquinolines, which is a well-established route to 
morphinans and a key reaction in the total synthesis of opium alkaloids by Kenner Rice.  In the 
original work of Grewe and Friedrichsen18 and Morrison et al.19 it was found that cyclization of 
(±)-4 provides a mixture of 5 and 6 with the desired compound 5 required for the synthesis of the 
natural opium alkaloids as the minor product (Scheme 02).  Rice and coworkers developed a 
blocking strategy for the synthesis of the desired compound20
                                                 
18 Grewe R., Friedrichsen W.  Chem Ber.  1967, 100, 1150. 
; however we wished to exploit the 
inherent preference for the formation of 6 to prepare novel morphinan-like structures as 
described below. 
19 Morrison G.C., Waite R.O., Shavel J.  Tetrahedron Lett.  1967, 4055.   
20 Rice K. C. J. Org. Chem.  1980, 45, 3135 – 3137. 
N
O
HO
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Natural (-)-Morphine
NO
HO
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O
(+)-Naloxone
MeO
OH
O
 Analogues
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a
b
c
NR
O
NR
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Scheme 02.  Grewe cyclization of (±)-4 provided the undesired compound 6 as the major isomer. 
 
 Our efforts began with the preparation of amine 7 and acid 8 as illustrated in 
Scheme 03.  Compound 7 was prepared from commercially available m-anisaldehyde 9 via 
hydrogenation of the cyanoformate intermediate 10 at 50 psi.  Treating behzaldehyde 11 with 
sodium bisulfite then potassium cyanide produced cyanohydrin 12 which was reduced to 8 with 
tin (II) chloride in acid.  Direct condensation of amine 7 and acid 8 at 200 oC readily afforded 
amide 13 in 90% yield.  Bischler-Napieralski cyclization of 13 and in situ reduction of the 
intermediate imine (14) with sodium borohydride generated (±)-15.   Alkylation of the secondary 
amine with sodium bicarbonate and 1-bromopropane (60 %) followed by birch reduction with 
sodium metal in ammonia provided (±)-16 (70 %) yield.  Formation of ketone (±)-17 from the 
enol ether was accomplished with dilute acid in THF (50 %), and Grewe cyclization of (±)-17 
generated (±)-2a in a yield of only 20%.  
 
 
N
MeO
HO
MeO
N
H
O
N
H
O
HO
MeO
OH
MeO
 +
(+/-)-4 65
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Scheme 03.   Synthetic route to compound (±)-2a. 
 
 Due to the low yield of the cyclization of 17, we studied the optimization of our 
key reaction.  The Grewe cyclization of appropriately substituted hexahydroisoquinolines is 
greatly facilitated by the presence of an electron withdrawing group on the amine nitrogen and a 
hydroxy group at the para-position to the point of ring closure.21  Since the work of Leimgruber22
                                                 
21 Brossi A., Schmidhammer H.  Can. J. Chem.  1982, 60, 3055 – 3060. 
 
22 Leimgrber W., Moasci E.  1972, US Pat 3634429. 
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and later Kenner Rice20 had shown that N-acyl amines undergo Grewe or Grewe-like cyclization 
in a much more facile manner than the corresponding amines, we opted to study the readily 
removable N-formyl substituent in the Grewe cyclization.  Therefore, Birch reduction of 
compound (±)-15 was followed by formylation with neat ethyl formate to provide (±)-18 
(Scheme 04).  
 
 
 
 
 
 
 
 
 
Scheme 04.  Synthesis of (±)-19. 
 
Indeed, Grewe cyclization of (±)-18 with concentrated sulfuric acid in ether leads to (±)-19 in an 
improved yield of 52 %.  Isolation of (±)-20·HCl was accomplished nearly quantitatively by 
treating (±)-19 with a refluxing solution of 4:1 MeOH/con. HCl.  Substitution of the amine 
hydrogen with propyl, allyl or cyclopropyl methyl is next, and is not expected to give rise to any 
difficulties.   
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2
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1.2 SYNTHETIC PREPARATION OF THE AROMATIC UNSUBSTITUTED SERIES 
 Morphine is principally metabolized in the liver by glucronidation.  In humans, 
about 44 – 55 % of morphine is metabolized to morphine-3-glucuronice (M3G), 9 – 15 % to 
morphine-6-glucoronide (M6G), 8 – 10 % excreted as morphine and the remainder converted 
into numerous minor metabolites23, 24 (Scheme 05).  Similarly, (+)-Naloxone (Scheme 01) is 
glucuronidated in the liver at its phenolic site.  (+)-Naloxone would be an ideal drug candidate 
for our purposes, however, metabolism of this compound happens too quickly in humans; its 
half-life is only about 60 minutes.25
 
  Because of this, we are interested in developing compounds 
lacking substitution on the aromatic ring.    
 
 
 
 
 
 
 
                                                 
23 Anderson G., Christrup L.  J. Pain Sympton Manage, 2003, 25, 74 – 91. 
24 Christrup L.  Acta Anaesthesiol Scand, 1997, 41, 116-122. 
25 Ngai, S. H., Berkowitz, B., Yang, J., Hampstead, J., Spector, S.  Anesthesiology, 1976, 44, 
398-401. 
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Scheme 05.  Glucronidation of morphine occurs in the liver via the enzyme UDP-glucoronosyl 
transferase (UGT). 
 
The synthesis of the aromatic unsubstituted morphinan series of compounds proceeded as 
follows.  Condensation of commercially available m-hydroxyphenylacetic acid 21 with amine 7 
afforded amide 22 (80 %, Scheme 06).  Beischler-Napieralski cyclization of amide 22 generated 
the 3,4-dihydroisoquinoline 23 (50 %), which underwent smooth O-demethylation with 48 % 
HBr to afford the phenolic 3,4-dihydroisoquinoline 24 in good yield (90 %).  Reduction of imine 
24 was carried out with NaBH4, to provide tetrahydroisoquinoline (±)-25 (40 %).  Birch 
reduction of (±)-25 afforded diene (±)-26 (85 %), which was N-formylated with neat ethyl 
formate to (±)-27 (70 %).  The Grewe cyclization of (±)-27 is expected to go smoothly in 
concentrated sulfuric acid in ether at room temperature to give (±)-28, which could then be 
triflated and reduced to intermediate (±)-30.  Acid hydrolysis of (±)-29 followed by substitution 
is anticipated to complete the synthesis of compounds (±)-3a-c.           
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Scheme 06.  Synthesis of compounds (±)-3a-c. 
 
1.3 Future Directions:  Asymmetric Transfer Hydrogenation, A Route to the (+)-isomers 
Ultimately, once this synthesis is complete, it is our desire to investigate a method of 
producing these compounds as the unnatural enantiomers.  These enantiomers would not share 
the specific actions of the natural (-)-isomers, and would be opioid receptor innactive.   We have 
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focused our attention on the work of Kenner Rice26 who has prepared asymmetric 
dihydroisoquinolines in good yield and high ee utilizing a Noyori chiral Ru catalyst.27
 
  Based on 
this work, we are encouraged to employ the enantioselective reduction of the cyclic imines 14 
and 24 with a chiral Ru (II) complex of suitable design as illustrated in Scheme 07.      
Scheme 07.  Asymmetric transfer hydrogenation of cyclic imines 14 and 24 catalyzed by a chiral 
Ru (II) complex. 
 
 
 
 
 
 
 
 
                                                 
26 Personal reference. 
27 Uematsu, N., Fujii, A., Hashiguchi, S., Ikariya, T., Noyori, R.  J. Am. Chem. Soc.  1996, 118, 
4916 – 4917. 
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CHAPTER TWO: 
THE SYNTHESIS OF CORTICOSTERONE-GLUCURONIDE 
 Understanding the role of the metabolism of neurotransmitters and 
neuromodulator metabolites is required in order to develop a deeper understanding of brain 
functions.  Neurosteroids are an important class of neuromodulators that can either activate or 
inactivate neuron-neuron communications, thereby mediating many brain functions.28
human adrenal cortisol, displays an intense immunospuppresive effect at the time of delivery.  
However, recent work has shown that it produces dramatic glial and immune activation and a 
proinflammatory response later in time.  Corticosterone, like morphine, is glucuronidated in its 
metabolic pathway.  The aim of this research was to synthesize Corticosterone-glucuronide 
(CortG) and test whether the glucuronidation is the cause of the eventual proinflammatory 
effects of corticosterone.      
  For 
example, it has been known for some time that the neurosteroid corticosterone, the rat version of  
 
2.1 SYNTHETIC ROUTE TO CORTG 
 Scheme 08 illustrates the synthesis of CortG and commences with the treatment 
of commercially available D-(+)-glucuronolactone 31 with triethylamine in methanol followed 
by treatment with pyridine and acetic anhydride to generate 32 in 60 % yield.  Deacylation of 32 
at the anomeric position was accomplished with tributyltin methoxide (67 %) followed by 
subjection to potassium carbonate and trichloroacetonitrile to provide the corresponding 
trichloroacetimidate 33 (53 %).  Compound 33 was coupled to commercially available 
corticosterone 34 with boron trifluoride ether complex to provide 35 (34 %).  Removal of the 
                                                 
28 Stoffel-Wagner, B.,  Ann. NY Acad. Sci., 2003, 1007, 64-78. 
  
14 
acyl groups of 35 was accomplished with sodium hydroxide in methanol to provide the desired 
carboxylic acid 36 in a 10 % yield.   
 
 
Scheme 08.  Synthesis of CortG 36. 
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CHAPTER 3: 
EXPERIMENTAL METHODS AND CHARACTERIZATION 
3.1 PROCEDURES AND CHARACTERIZATION OF COMPOUNDS 
 
O-(Ethoxycarbonyl)-3-methoxymandelonitrile (10)29
 
: 
 
 
 
To a stirred solution of 30 g (220 mmol) of m-anisaldehyde 9 and 26.3 g (242 mmol, 23.3 
ml) of ethyl chloroformate in 44 ml of THF cooled on an ice bath, was added 15.8 g (242 mmol) 
of KCN dissolved in 30 ml of H2O in one portion.  The reaction mixture was stirred for 4 h at 5 
˚C and then slowly warmed to room temperature overnight.  60 ml of water was added, the 
mixture was transferred to separatory funnel, and the aqueous solution was extracted with ether 
(4 x 25 ml).  The organic extracts were washed with fresh water, dried over anhydrous Mg2SO4 
and evaporated to 49.3 g (95 % crude yield) of a yellow oil.  The crude material was carried on 
without purification.   1H NMR (500 MHz, CDCl3):  NMR δ 7.34 (1 H, t, J = 8 Hz), 7.10 (1 H, 
broad d, J = 7.7 Hz), 7.03 (1 H, t, J = 2 Hz), 6.99 (1 H, dd, J = 2.5, 8.5), 6.21 (1 H, s), 4.27 (2 H, 
m), 3.82 (3H, s), 1.32 (3 H, t, J = 7 Hz).  
 
 
 
                                                 
29 Rapaport H, Kashdan D, Schwarz J.  J. Org. Chem.  1982, 47, 2638 – 2643.  
O
MeO Cl
O
OEt
KCN, THF/H2O
OCOOEt
MeO
CN
109
  
16 
2-(m-Methoxyphenyl)ethylamine (7) 29: 
 
 
 
 
500 ml of absolute ethanol and 2.5 g of 5 % Pd/C catalyst was added to a 2000 ml Parr 
Shaker reaction vessel.  20 g (85 mmol) of cyanoformate 10 was transferred to the reaction 
vessel with the aid of 350 ml of absolute ethanol, followed by 16.8 g (170 mmol, 9.1 ml) of 
concentrated H2SO4.  The mixture was shaken under 50 psi for 12 h.  Celite was added to the 
mixture and this solution was filtered through a thin celite pad.  The solvent was evaporated to a 
yellow oil, water (50 ml) was added, and the cooled aqueous solution was made alkaline with 4 
M sodium hydroxide.  The solution was extracted with 4 x 30 ml of ether, and organic extracts 
were combined, dried over anhydrous Mg2SO4, and evaporated to a yellow oil which was 
Kugelrohr distilled to afford 11.2 g (85 %) of phenethylamine 7 as a thin, clear oil. 1H NMR 
(500 MHz, CDCl3):  NMR δ 7.20 (1 H, t of d, J = 1, 7.5 Hz), 6.78 – 6.73 (3 H, m), 3.78 (3 H, s), 
2.94 (2 H, t, J = 7 Hz), 2.70 (2 H, t, J = 7 Hz), 1.05 (2 H, broad s). 
 
 
 
 
 
 
OCOOEt
MeO
CN
H2, Pd/C, H2SO4
EtOH
MeO NH2
710
  
17 
Cyanohydrin (12)30
 
: 
 
 
 
20 g (131 mol) of 3-hydroxy-4-methoxy benzaldehyde was added in small portions at 50 
˚C to 40 ml of 40 % aqueous NaHSO3 and 60 ml water.  This mixture was cooled rapidly to -5 
˚C, treated dropwise at -5 ˚C with 17.1 g (263 mmol) KCN dissolved in 26 ml of water during 1 
– 1.5 h.  The solution was stirred for 0.5 h, acidified with 5 N H2SO4 at -5 ˚C (pH = 2).  The 
mixture becomes white and thick upon addition to 5 M H2SO4.  The mixture was extracted after 
another 0.5 h of stirring with ether (4 x 30 ml).  The organic extracts were combined, washed 
with fresh water, dried over Mg2SO4 and evaporated to a yellow solid.  The crude residue was 
recrystallized from dichloroethane and dried to yield 19.3 g (82 %) of the cyanohydrin as a light 
yellow solid. 1H NMR (500 MHz, DMSO-d6):  NMR δ 9.25 (1 H, s), 6.95 – 6.83 (3 H, m), 5.57 
(1 H, d J = 6 Hz), 3.76 (3 H, s).   
 
 
 
 
 
 
 
                                                 
30 Grewe R., Fischer H.  Chem. Ber.  1963, 96, 1520 – 1528. 
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(3-Hydroxy-4-methoxyphenyl)acetic Acid (8)30,31
 
:   
 
 
A stirring solution of 10 g (56 mmol) of 12 in 12.8 ml of AcOH and 15.9 g (84 mmol) 
SnCl2·2 H20 was treated with 16.3 ml of concentrated HCl.  The mixture was heated for 4 h at 
110 ˚C, cooled to room temperature, filtered through celite to get rid of excess SnCl2, and diluted 
with 20 ml of water.  This aqueous solution was extracted continuously with CHCl3 for 12 h.  
The organic extracts were evaporated to a light orange, crude solid which was heated to solution 
in 5 ml of 2-propanol and treated with 1 ml of concentrated aqueous NH3 to afford crystalline 
material almost immediately.  The slurry was cooled to room temperature, and the solid was 
filtered, washed with of 2-propanol, and dried to afford 11.5 g of light pink 8·NH3·H2O which 
was heated to solution in about 20 ml of H2O and treated with 20 ml of concentrated HCl.  After 
the mixture was cooled on an ice bath, the acid was filtered, washed with cold 6 N HCl, and 
dried to afford 4.7 g (46 %) of 8 as a white solid, mp 129 – 130.5 ˚C; 1H NMR (500 MHz, 
CDCl3):  NMR δ 10.3 (1 H, broad s), 6.84 (1 H, d, J = 2 Hz), 6.79 – 6.73 (2 H, m), 5.59 (1 H, 
broad s), 3.86 (3 H, s), 3.54 (2 H, s). 
 
 
 
 
 
                                                 
31 Rice K, Brossi A.  J. Org. Chem.  1980, 45, 92 – 601. 
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Amide (13)30:   
 
 
 
 
A mixture of 5.5 g (30 mmol) of dry acid 8 and 4.6 g (30 mmol) of dry amine 7 in a 100 
ml flask was vac/nitrogen purged (4 x).  The flask was placed in a silicon oil bath and stirred and 
heated for 2 h (bath temperature 195 – 200 ˚C) while passing a nitrogen sweep over the melt.  
The clear melt was cooled to room temperature, heated to solution in about 4 ml of AcOH, and 
diluted with 4 ml of H2O.  The solution was slowly cooled to room temperature, placed on an ice 
bath, and when crystallization was complete, the orange solid was filtered, and washed with 1:1 
AcOH/H2O.  The solid was recrystallized from ethyl acetate to produce 6.2 g (65 %) of amide 13 
as a white solid, mp 112 – 115 ˚C; 1H NMR (500 MHz, CDCl3):  NMR δ 7.14 (1 H, m), 6.76 – 
6.71 (3 H, m), 6.64 – 6.57 (3 H, m), 5.63 (1 H, s), 5.39 (1 H, broad s), 3.87 (3 H, s), 3.76 (3 H, s), 
3.46-3.39 (4 H, m), 2.68 (2 H, t, J = 7 Hz).  
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Isoquinoline (±)-15·TsOH·H2O30,32
 
: 
 
 
 
 
 
 
 
 A stirred, refluxing solution of 2.0 g (6.3 mmol) of amide 13 in 32 ml of acetonitrile was 
treated with 3.8 ml (40.6 mmol) of POCl3 during 10 min (exothermic reaction).  The mixture was 
refluxed for 1 hr and cooled to room temperature.  The solvent and POCl3 was distilled off to 
leave behind a red foam which was heated to solution in 9 ml of water and allowed to reflux for 
1 h (exothermic reaction, add water slowly).  The mixture was cooled until a yellow oil 
separated, 6.4 ml of THF was added, and passage of nitrogen through the solution was begun 
and continued for the duration of the reaction.  The solution was cooled to 0 – 5 ˚C during 0.5 h, 
and sufficient concentrated aqueous NH3 was added (T < 15 ˚C) to give a final pH of 8.5 – 9.5.  
The reaction mixture, which contained a yellow solid, was cooled to 0 ˚C, and 48 mg (12.7 
mmol) of NaBH4 was quickly added in portions.  When the addition of NaBH4 was complete, the 
mixture was stirred at 0 ˚C for 0.5 h, and then at room temperature for 2 h.  The yellow reaction 
mixture turns tan upon addition of NaBH4.  The flow of nitrogen was discontinued, 10 ml of 
CHCl3 was added along with 20 ml of water.  Stirring was continued until the solids had 
dissolved.  The biphasic mixture was transferred to a seperatory funnel, the organic layer was 
collected, and the aqueous reextracted with CHCl3 (4 x 10 ml).  The combined, wet CHCl3 
extracts were evaporated to a grey-purple foam and heated in 11 ml of water containing 1.1 g 
                                                 
32 Rice, K.  J. Org. Chem.  1980, 45, 3135 – 3137. 
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(5.8 mmol) of TsOH·H2O until the grey-purple foam turned into a yellow solid.  After being 
cooled to 5 ˚C for 1 h, the yellow solid was filtered and washed with cold water to obtain 2.0 g 
(65 %) of (±)-15·TsOH·H2O, which was carried on without purification. 1H NMR (500 MHz, 
CDCl3):  NMR δ 7.50 (2 H, d, J = 8 Hz), 7.06 (2 H, d, J = 8 Hz), 6.92 (1 H, d, J = 2 Hz), 6.83 – 
6.53 (5 H, m), 4.63 (1 H, m), 3.79 (3 H, s), 3.76 (3 H, s), 3.50 – 3.30 (2 H, m), 3.15 (2 H, d, J = 7 
Hz), 3.0 (2 H, m).   
 
Isoquinoline (±)-1531,32: 
 
 
  
 
 
A mixture of 2.0 g (4.1 mmol) of (±)-15·TsOH·H2O and 2 ml of methanol was heated to 
solution.  To the stirred mixture was added in order 10 ml of CHCl3, 1.33 ml of concentrated 
aqueous NH3, and 6.7 ml of water.  The water layer was decanted into a seperatory funnel while 
the thick, cloudy organic layer was transferred to a beaker.  The aqueous layer was extracted 
with CHCl3 (4 x 5 ml) and combined with the cloudy organic layer from above.  This CHCl3 
mixture was filtered through a fritted funnel to collect a white solid, and the mother liquor was 
evaporated to a brown residue.  This brown residue and the white solid collected was heated in 
about 10 ml of butyronitrile until the mixture was tan and homogeneous.  This thick solution was 
cooled to room temperature, then to 0 ˚C for 1 h.  The tiny crystals were filtered and washed with 
ice-cold butyronitrile to provide 2.5 g (60 %) of (±)-15 as a white solid, mp 199 – 201 °C; 1H 
NH TsOH H2O
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NMR (500 MHz, CDCl3):  NMR δ 7.14 (1 H, d, J = 8.5 Hz), 6.84 (1 H, s), 6.79 (1 H, d, J = 8.14 
Hz), 6.75 – 6.69 (2 H, m), 6.62 (1 H, d, J = 2.6), 5.63 (1 H, s, broad), 4.09 (1 H, dd, J = 3.5, 10.3 
Hz), 3.86 (3 H, s), 3.77 (3 H, s), 3.20 – 3.12 (2 H, m), 2.90 – 2.70 (4 H, m).  
 
Amine (±)-37: 
 
 
 
 
  
 
1.3 g (4.4 mmol) in 17 ml of DMF was treated with 1.8 g (21.8 mmol) of NaHCO3 and 
0.4 ml (4.8 mmol) of distilled 1-bromopropane.  The solution was heated to 80 – 90 ˚C and 
allowed to stir for 18 h.  The mixture was cooled to room temperature, diluted with 3 ml of H2O 
and extracted with CHCl3 then brine.  The organic extracts were combined, dried over Mg2SO4, 
and evaporated to a brown residue that was purified by column chromatography in 97:2:1 
CHCl3/MeOH/con. NH3 (Rf = 0.30, stained in CAM) to provide 1.1 g (73 %) of the desired 
alkylated product as a yellow oil. 1H NMR (500 MHz, CDCl3):  NMR δ 6.76 (1 H, d, J = 2 Hz), 
6.72 (1 H, d, J = 8 Hz), 6.60 – 6.53 (4 H, m), 5.63 (1 H, broad s), 3.85 (3 H, s), 3.79 (1 H, t, J = 7 
Hz), 3.74 (3 H, s), 3.21 (1 H, m), 2.99 – 2.82 (4 H, m), 2.66 (1 H, q), 2.50 (3 H, t, J = 7.5 Hz), 
1.44 (2 H, m), 0.79 (3 H, t, J = 7.5 Hz). 13C (75 MHz, CDCl3):  NMR δ 157.88, 145.39, 145.08, 
135.71, 133.69, 130.32, 129.49, 121.34, 116.03, 113.37, 111.81, 110.49, 62.72, 56.16, 55.92, 
55.36, 43.75, 41.49, 25.47, 21.25, 11.99.  
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Diene (±)-16: 
 
 
 
 
 
10.5 ml of ammonia was condensed into a 3 neck flask in a -78 ˚C (dry ice/acetone) bath 
under a nitrogen atmosphere, and 423 mg (18.4 mmol) of sodium metal was added.  To this blue 
solution, was added slowly 523 mg (1.5 mmol) of (±)-37 dissolved in 10.5 ml of a 1:1 mixture of 
t-BuOH/THF at -78 ˚C.  The dry ice/acetone bath was switch to a CHCl3/liquid nitrogen bath and 
the reaction mixture was stirred between -55 and -65 ˚C for 2 h.  The cold bath was dropped and 
the mixture was allowed to warm to room temperature.  The white residue left over was 
dissolved in 5 ml of water, transferred to a separatory funnel, and extracted with CHCl3 (4 x 2 
ml).  The organic extracts were combined, dried over Mg2SO4, and evaporated to 31 mg (59 %) 
of (±)-16 as a yellow residue which was carried on without purification. 1H NMR (500 MHz, 
CDCl3):  NMR δ 6.82 (1 H, d, J = 2 Hz), 6.72 (2 H, d, J = 8.2), 6.88 (1 H, dd, J = 2, 8), 5.80 (1 
H, broad s), 4.58 (1 H, t, J = 3.5 Hz), 3.83 (3 H, s), 3.52 (3 H, s), 3.08 (1 H, m), 2.99 (1 H, m), 
2.72 – 2.39 (9 H, m), 2.18 (1 H, m), 1.63 (1 H, broad d, J = 16.8 Hz), 1.35 (2 H, m), 0.73 (3 H, t, 
J = 7.4 Hz). 13C (75 MHz, CDCl3):  NMR δ 152.63, 145.36, 144.93, 124.37, 120.87, 115.59, 
110.56, 90.66, 63.32, 56.21, 55.62, 54.04, 43.31, 37.54, 33.72, 30.14, 29.23, 25.89, 22.92, 21.24, 
11.98.   
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Ketone (±)-17: 
 
 
 
 
 
 
 
 322 mg of (±)-16 (0.9 mmol) in 32 ml of THF was treated with 8.2 ml of a 5 % aqueous 
solution of H2SO4.  The reaction mixture was allowed to stir for 72 h at room temperature, 
washed with saturated NaHCO3, dried over Mg2SO4, and evaporated to a dark yellow oil.  The 
crude was purified by column chromatography in 97:2:1 CHCl3/MeOH/con. NH3 (Rf = 0.2, 
stained in CAM) to afford 158 mg (51 %) of the pure ketone as a yellow oil. 1H NMR (500 MHz, 
CDCl3):  NMR δ 6.82 (1 H, d, J = 2 Hz), 6.72 (1 H, d, J = 8.2 Hz), 6.66 (1 H, dd, J = 2.0, 8.2 
Hz), 3.84 (3 H, s), 3.11 (1 H, broad t, J = 5.9 Hz ), 3.01 (1 H, m), 2.83 – 2.67 (4 H, m), 2.63 (1 H, 
dd, J = 5.7, 13.9), 2.47 – 2.30 (4 H, m), 2.14 (3 H, m), 1.70 (1 H, broad d, J = 17.7 Hz), 1.39 (2 
H, m), 0.78 (3 H, t, J = 7.4 Hz). 13C (75 MHz, CDCl3):  NMR δ 210.81, 145.52, 145.15, 131.37, 
125.7, 120.81, 115.53, 110.61, 63.84, 56.19, 55.87, 44.28, 43.13, 39.18, 36.92, 29.85, 28.89, 
26.64, 21.19, 12.02. 
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Amine (±)-2a33
 
: 
 
 
 
 
 
 
 
100 mg (0.3 mmol) of amine (±)-17 was placed into a cold finger and treated with 2 ml of 
85 % H3PO4.  The mixture was heated on a sand bath to about 80 ˚C and allowed to stir for 20 h 
while nitrogen was bubbled through the solution.  The mixture was cooled to room temperature, 
diluted with 6 ml of cold water, and treated with concentrated NH3 until pH = 8.  The aqueous 
mixture was extracted with CHCl3 (4 x 3 ml).  The organic layers were combined, dried over 
Mg2SO4 and evaporated to provide the crude product as a brown residue which was purified by 
column chromatography in 95:4:1 CHCl3/MeOH/con. NH3 (Rf = 0.29, stained in CAM) to 
provide 21 mg of (±)-2a (21 %). 1H NMR (500 MHz, CDCl3):  NMR δ 6.68 (1 H, s), 6.62 (1 H, 
s), 3.84 (3 H, s), 3.14 (1 H, broad s), 3.04 (1 H, dd, J = 2, 14 Hz), 2.91 (1 H, d, J = 18.6 Hz), 2.65 
– 2.17 (10 H, m), 2.11 (1 H, td, J = 2.8, 12.3 Hz), 1.91 (2 H, m) 1.55 (2 H, m), 1.42 (1 H, dt, J = 
2.4, 12.7 Hz), 0.92 (3 H, t, J = 7.4 Hz). 13C (75 MHz, CDCl3):  NMR δ 209.89, 145.61, 144.32, 
123.99, 113.65, 108.54, 57.09, 56.34, 55.34, 51.94, 44.69, 43.83, 41.81, 41.43, 41.27, 27.05, 
24.30, 20.95, 12.21. 
 
 
 
                                                 
33 Grewe R., Friedrichsen W.  Chem. Ber.  1967, 100, 1550 – 1558.  
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Amine (±)-3832: 
 
 
 
 
 
 
 
 
 27 ml of ammonia gas was condensed into a three-neck flask in a -78 ˚C bath (dry 
ice/acetone) and treated with 0.6 g (27.6 mmol) of sodium metal under nitrogen.  1.2 g (3.9 
mmol) of (±)-15 dissolved in 27 ml of a 1:1 mixture of t-BuOH/THF was added slowly to the 
blue solution.  The dry ice/acetone bath was changed to a CHCl3/liq nitrogen bath and the 
mixture was stirred between -55 and -65 ˚C for 2 h.  The cold bath was dropped, and the reaction 
was allowed to warm to room temperature open to air.  The white residue left over was diluted 
with about 8 ml of water and transferred to a separatory funnel.  The aqueous mixture was 
extracted with CHCl3 (4 x 5 ml), and organic extracts were combined, dried over Mg2SO4, and 
evaporated to 0.9 g (72 %) of (±)-38 as a yellow solid.  The crude was one spot by TLC in 90:9:1 
CHCl3/MeOH/con. NH3 (Rf = 0.4, stained in CAM), and was carried on without purification. 1H 
NMR (500 MHz, CDCl3):  NMR δ 6.80 – 6.76 (2 H, m), 6.68 (1 H, dd, J = 2, 8.2 Hz), 5.68 (1 H 
broad s), 4.65 (1 H, broad t, J = 2.7 Hz), 3.86 (3 H, s), 3.55 (3 H, s), 3.30 (1 H, broad d, J = 11.4 
Hz), 3.08 – 2.87 (3 H, m), 2.79 (1 H, m), 2.67 - 2.48 (4 H, m), 2.0 (2 H, m).   
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Formamide (±)-1832: 
 
 
 
 
 
 
 
 
 693 mg (2.3 mmol) of (±)-38 was treated with 10 ml of freshly distilled ethylformate and 
refluxed for 12 h under nitrogen in a cold finger.  The solvent was evaporated to a tan residue 
was flashed in 96:3:1 CHCl3/MeOH/con. NH3 (Rf = 0.3, stained in CAM) to yield 526 mg (69 
%) of the desired (±)-18 as a white foam.  TLC of this material in showed two closely running 
spots corresponding to the two rotamers in a 2:1 ratio, which were apparent by the NMR 
spectrum. 1H NMR (500 MHz, CDCl3):  NMR δ 7.93 (0.50 H, s), 7.41 (1 H, s), 6.74 – 6.66 (4 H, 
m), 6.51 (1 H, dd, J = 2, 8 Hz), 5.66 (1 H, s), 5.60 (0.5 H, s), 4.75 (0.5 H, t, J =6.5 Hz), 4.67 (1.5 
H, dt, 3.5, 13.5), 4.40 (1 H, m), 3.83 (5 H, two s corresponding to methoxy group), 3.67 (1 H, dd, 
J = 9.4 Hz), 3.55 (5 H, two s corresponding to methoxy group), 3.39 (0.5 H, m), 3.10 – 2.90 (5 
H, m), 2.80 – 2.57 (6 H, m) 2.18 (2 H, m), 1.90 (1 H, dd, J = 4, 17 Hz), 1.80 (0.5 H, dd, J = 4, 17 
Hz).  
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Formamide (±)-19: 
 
 
 
 
 
 
 
 To a well stirred suspension of 114 mg (0.35 mmol) of (±)-18 and 3.46 ml of ether were 
added dropwise 2.21 ml (42 mmol) of 80 % H2SO4 at 0 ˚C under a nitrogen atomosphere during 
1.5 h.  The resulting solution was then allowed to stir at room temperature for 20 h. About 6 ml 
of ice-cold water was added to the yellow mixture and the aqueous solution was extracted with 
1:1 CHCl3/2-propanol (6 x 10 ml).  The organic layers were combined, washed with fresh water, 
dried over Mg2SO4, and evaporated to give the crude product as a tan foam.  The crude was 
purified by column chromatography in 90:1 MeOH/CHCl3 (Rf = 0.25, stained in CAM) to 
isolate pure (±)-19 as a white solid (52 %).  TLC of this material appears as two very closely 
running spots corresponding to the two rotamers, in about a 1:1 ratio, apparent by the NMR 
spectrum. 1H NMR (500 MHz, CDCl3):  NMR δ 8.17 (1 H, s), 8.01 (1 H, s), 6.72 (2 H, s), 6.62 
(2 H, d, J = 6.2 Hz), 5.56 (2 H, d, J = 4.2 Hz), 4.81 (1 H, dd, J = 3.7, 5.8), 4.21 (1 H, dd, J = 4.9, 
13.8 Hz), 3.85 (6 H, two s corresponding to methoxy groups), 3.31 (1 H, dd, J = 4.7, 13.5 Hz), 
3.19 – 2.96 (5 H, m), 2.66 (2 H, m), 2.50 (1 H, td, J = 3.7, 13.3 Hz), 2.44 – 2.22 (4 H, m), 2.30 – 
2.20 (2 H, m), 2.18 – 2.0 (2 H, m), 1.95 – 1.85 (1 H, m), 1.80 – 1.50 (9 H, m). 13C (75 MHz, 
CDCl3):  NMR δ 203.56, 208.32, 160.74, 160.71, 146.13, 146.04, 144.95, 144.89, 127.99, 
127.46, 127.38, 114.07, 113.94, 108.63, 56.36, 56.34, 52.94, 51.67, 51.63, 45.57, 44.04, 42.72, 
42.51, 42.37, 42.18, 40.99, 40.93, 40.87, 40.15, 33.96, 32.51, 31.19, 26.53, 26.41.     
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Amine (±)-20: 
 
 
 
 
 
 
 
 21 mg (0.07 mmol) of (±)-19 was treated with about 1 ml of a 4:1 MeOH/HCl solution 
and refluxed under nitrogen for 16 h.  The mixture was allowed to cool to room temperature, 
diluted with water, basified with con. NH3, and extracted with 3:1 CHCl3/2-propanol.  The 
organic extracts were combined, dried over Mg2SO4, and evaporated to 17 mg of (±)-20 as the 
free base. 1H NMR (500 MHz, CDCl3):  NMR δ 6.68 (1 H, s), 6.63 (1 H, s), 3.84 (3 H, s), 3.28 
(1 H, dd, J = 6, 3.2 Hz), 3.11 – 2.97 (2 H, m), 2.74 – 2.70 (2 H, m), 2.64 (1 H, td, J = 3, 12.7 Hz) 
2.47 – 2.32 (3 H, m), 2.28 – 2.14 (3 H, m), 1.51 (2 H, qd, J = 4.9, 13 Hz), 1.43 (2 H, dt, J = 2.5, 
12.5 Hz). 13C (75 MHz, CDCl3):  NMR δ 209.56, 145.65, 144.43, 129.63, 128.78, 113.76, 
108.67, 56.34, 52.30, 50.51, 44.51, 42.47, 41.85, 41.49, 38.06, 33.81.   
 
Amide (22): 
 
 
 
 
 
 
 
 
 A mixture of 10 g (60 mmol) of commercially available 3-methoxyphenylacetic acid 21 
and 9.10 g (60 mmol) of pure amine 7 was heated to 200 ˚C in a silicon oil bath with a nitrogen 
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sweep.  When the mixture was completely melted together, the melt was allowed to stir for 2 h, 
and cooled to room temperature.  The melt was dissolved in about 15 ml of CHCl3 and washed 
with fresh water and brine.  The organic portion was dried over Mg2SO4 and evaporated to a 
yellow oil which was purified with column chromatography in 1:1 Hex/EtOAc (Rf = 0.33, 
stained in CAM) to isolate 13.9 g (78 %) of 22 as a clear oil. 1H NMR (500 MHz, CDCl3):  NMR 
δ 7.20 (1 H, t, J = 8 Hz), 7.12 (1 H, t, J = 8 Hz), 6.8 (1 H, dd, J = 2.5, 8 Hz), 6.73 – 6.69 (3 H, m), 
6.60 – 6.58 (2 H, m), 5.41 (1 H, broad s), 3.76 (3 H, s), 3.75 (3 H, s), 3.49 (2 H, s), 3.44 (2 H, q, J 
= 6.8), 2.68 (2 H, t, J = 6.9 Hz).   
 
Imine (23·HBr)33
 
: 
 
 
 
 
 
 
 
 
 To a solution of 8 g (27 mmol) of 22 in 33 ml of acetonitrile were added 4.2 ml (45 
mmol) of POCl3.  At room temperature nitrogen was passed through this mixture during 0.5 h.  
Then the mixture was refluxed for 1.0 h under nitrogen, evaporated by distillation, cooled to 0 – 
5 ˚C and basified with con. NaOH.  The aqueous mixture was extracted with CH2Cl2, and the 
organic extracts were combined, washed with fresh water and brine, dried over Mg2SO4, and 
evaporated to an oily residue which was dissolved in 5 ml of MeOH.  To this solution, sufficient 
con. HBr was added to give pH of 1.  Addition of ether and cooling to 0 ˚C overnight produced 
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7.35 g (76 %) of crude 23·HBr, which was isolated as a light yellow solid by vacuum filtration 
and carried on without purification. 1H NMR (500 MHz, CDCl3):  NMR δ 7.84 (1 H, d, J = 9 
Hz), 7.19 (1 H, t, J = 8 Hz), 7.05 (1 H, t, J = 2 Hz), 6.93 (1 H, d, J = 7.7), 6.88 (1 H, dd, J = 2.5, 
8.8), 6.81 – 6.73 (2 H, m), 4.59 (2 H, s), 3.96 (2 H, td, J = 3.4, 8 Hz), 3.88 (3 H, s) 3.79 (3 H, s), 
3.04 (2 H, t, J = 7.8 Hz).  
 
Imine (24·HBr)33: 
 
 
 
 
 
 
 
 
 A solution of 2.35 g (6.5 mmol) of 23·HBr in 5.6 ml of con. HBr was refluxed for 50 
min. and evaporated to a thick, reddish-brown oil which was dissolved in 1.5 ml of MeOH.  This 
mixture was cooled on an ice bath, then Et2O was added, and the resulting mixture was kept at 0 
˚C overnight to yield 24·HBr as a tan, sticky solid which was isolated by gravity filtration.  This 
material was dried thoroughly to produce 1 g (44 %) of a tan solid that was carried on without 
purification. 1H NMR (500 MHz, DMSO-d6):  NMR δ 8.08 (1 H, d, J = 8.9 Hz), 7.12 (1 H, t, J = 
7.9), 7.08 (1 H, d, J = 2.5 Hz), 7.94 (2 H, dd, J = 2.6, 8.8 Hz), 6.83 – 6.74 (2 H, m) 6.68 (1 H, dd, 
J = 2, 7.8 Hz), 4.89 (2 H, s), 3.88 (3 H, s), 3.08, 3.01 (4 H, 2 t, J = 7.8 Hz).  
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Amine (±)-2533: 
 
 
 
 
 
 
 
 
 A stirred solution if 1 g (2.9 mmol) of 24·HBr in 8.2 ml EtOH was treated with 0.16 g 
(4.3 mmol) NaBH4 in small portions during 20 min while at 0 – 5 ˚C.  After the addition of 
NaBH4 was complete, the mixture was stirred for 15 min at room temperature, then cooled to 0 -
5 ˚C, and the excess NaBH4 was destroyed with 30 % AcOH to give a final pH of 5.  After 
evaporation, the residue was dissolved in H2O, rendered alkaline with con. NH3, and extracted 
with 2:1 CHCl3/2-propanol (3 x 5 ml).  The organic layers were combined, washed with brine, 
dried over Mg2SO4, and evaporated to an off-white solid, which was recrystallized from MeOH 
to produce 0.28 g (37 %) of (±)-25 as a white solid. 1H NMR (500 MHz, DMSO-d6):  NMR δ 
9.25 (1 H, s), 7.14 (1 H, d, J = 8.6 Hz), 7.08 (1 H, t, J = 7.7 Hz), 6.70 – 6.68 (3 H, m), 6.65 – 6.57 
(2 H, m), 3.97 (1 H, dd, J = 3.8, 9.3 Hz), 3.70 (3 H, s), 3.10 – 3.00 (2 H, m), 2.80 – 2.60 (4 H, 
m).  
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Diene (±)-2633: 
 
 
 
 
 
 
 
 
 To 1.85 ml distilled NH3 were added 26 mg (3.7 mmol) Li metal.  To the blue solution 
was added 1 ml of a 1:1 mixture of dry t-BuOH/THF at -78 ˚C.  Into this well stirred mixture a 
solution of 50 mg (0.19 mmol) of (±)-25 in 1.5 ml of 1:1 dry t-BuOH/THF was added dropwise 
during 10 min.  The cold bath was switched to a CHCl3/liq N2 bath and the mixture was allowed 
to stir at -55 - -65 ˚C for 1 h.  The cold bath was dropped, and the reaction was allowed to warm 
to room temperature.  The white residue was diluted with water and extracted with 3:1 CHCl3/2-
propanol.  The organic extracts were combined, dried over Mg2SO4, and evaporated to 28 mg (56 
%) of (±)-26 as a solid.  The solid was one spot by TLC in 90:9:1 CHCl3/MeOH/con. NH3 (Rf = 
0.4, stained in iodine).  This solid was carried on without purification. 1H NMR (500 MHz, 
CDCl3):  NMR δ 7.13 (1 H, t, J = 7.8 Hz), 6.66 (2 H, d, J = 7.9 Hz), 6.56 (1 H, s), 4.65 (1 H, 
broad d, J = 3.4 Hz), 3.55 (3 H, s), 3.47 (1 H broad d, J = 10.4 Hz), 3.08 – 2.97 (3 H, m), 2.81 (1 
H, m), 2.75 – 2.57 (3 H, m) 2.03 (2 H, broad dd, J = 17, 60.5 Hz).   
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Formamide (±)-2733: 
 
 
 
 
 
 
18 mg of (±)-26 in a cold finger was treated with about 2.5 ml of distilled ethylformate.  
The mixture was allowed to reflux for 12 under an N2 atmosphere.  Evaporation yielded a yellow 
residue, which was purified by column chromatography in 97:2:1 CHCl3/MeOH/con. NH3 (Rf = 
0.2, stained in CAM) to yield 14 mg (71 %) of (±)-17 as two rotamers in about a 1:1 ratio 
apparent by the 1H NMR. 1H NMR (500 MHz, CDCl3):  NMR δ 7.91 (1 H, s), 7.37 (1 H, s), 7.24 
– 7.07 (3 H, m), 6.67 – 6.54 (6 H, m), 4.80 (1 H, broad t, J = 6.1 Hz), 4.67, 4.66 (2 H, dt, J = 3.4, 
14.7 Hz), 4.4 (1 H, q), 3.71 (1 H, d, J = 11.5), 3.56, 3.54 (6 H, 2 s), 3.4 (1 H, m), 3.04 – 2.60 (12 
H, m) 2.2 – 1.8 (7 H, m).  
 
 
 
 
 
 
 
 
NH
MeO
H
26
OH
NCHO
MeO
H
Ethylformate
27
OH
  
35 
Glucopyranuronate (32)34
 
: 
 
 
 
 
 
 A solution of 8 g (45 mmol) of glucuronolactone 31 and Et3N (0.8 ml) in MeOH (60 ml) 
was stirred for 2 h at room temperature then the MeOH was removed by rotoevaporation.  The 
resulting black syrup was dissolved in pyridine (20 ml) and acetic anhydride (30 ml).  The 
mixture was allowed to stir in a cold room between 4 – 5 ˚C for 5 d.  The solvent was removed 
by rotoevaporation, Et2O was added to the resulting black residue, and the less soluble product 
was filtered to give a solid (β-isomer 32), which was recrystallized from 2-propanol to yield 4.69 
g (30 %) of 32 as a white solid.  The TLC of the recrystallized material was one spot when 
developed in 2:1 Hex/EtOAc (Rf = 0.29, stained in CAM).  [The TLC of the mother liquor 
showed two closely running spots in 2:1 Hex/EtOAc, presence of the desired β-isomer, 32 (Rf = 
0.29), and the α-isomer (Rf = 0.24).] 1H NMR (500 MHz, CDCl3):  NMR δ 5.74 (1 H, d, J = 7.8 
Hz), 5.29 (1 H, t, J = 9.2 Hz), 5.22 (1 H, t, J = 9.5 Hz), 5.13 (1 H, dd, J = 7.8, 9 Hz), 4.176(1 H, 
d, J = 9.6 Hz), 3.73 (3 H, s), 2.10 (3 H, s), 2.02 (6 H, s), 2.01 (3 H, s).       
 
 
 
 
 
                                                 
34 Nakajima, R., Ono, M., Aiso, S., Akita, H.  Chem. Pharm. Bull.  2005, 53, 684 – 687. 
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Glucopyranuronate (39)34: 
 
 
 
 
 
 A mixture of 2.95 g (7.9 mmol) of 32 and 2.4 ml (7.9 mmol) of tributyltin methoxide in 
45 ml dichloroethane was stirred for 5 h at 90 ˚C, and the whole mixture was evaporated to give 
a crude residue which was purified by column chromatograpy in 3:1 Hex/EtOAc (Rf = 0.17, 
stained in CAM) to give 1.59 g (61 %) of 39 as a white solid. 1H NMR (500 MHz, CDCl3):  
NMR δ 5.91 (1 H, t, J = 1.5 Hz), 4.94 (1 H, m), 4.78 (1 H, dd, J = 1, 17 Hz), 4.59 (1 H, t, J = 2 
Hz), 2.17 (6 H, s), 2.09 (3 H, s).   
 
Trichloroacetimidate donor (33)34: 
 
 
 
 
 
 
 A mixture of 2.34 g (7.0 mmol) of 39, 1.55 g of K2CO3, and 4 Å molecular sieves in 15.6 
ml of CH2Cl2 was stirred for 25 min at 0 ˚C under an N2 atmosphere.  A solution of 
trichloroacetonitrile in 7.8 ml of CH2Cl2 was added to the reaction mixture, and this mixture was 
stirred for 2 h at 0 ˚C.  The suspension was filtered through celite, and the filtrate was washed 
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with 7 % NaHCO3 (3 x 5 ml), dried over Mg2SO4, and concentrated to a foam.  The crude foam 
was purified by column chromatography in 3:1 Hex/EtOAc (Rf = 0.3, stained in CAM) to isolate 
1.88 g (60 %) of solid 33. 1H NMR (500 MHz, CDCl3):  NMR δ 8.71 (1 H, s), 6.62 (1 H, d, J = 
3.6 Hz), 5.61 (1 H, t, J = 10 Hz), 5.25 (1 H, dd, J = 9.6, 10.2 Hz), 5.13 (1 H, dd, J = 3.6, 10 Hz), 
4.48 (1 H, d, J = 10 Hz) 3.73 (3 H, s), 2.04 (6 H, s), 1.99 (3 H, s).   
 
Protected Corticosterone-glucuronide (35): 
 
 
 
 
 
 A mixture of 0.83 g (1.7 mmol) of 33, 0.30 (0.87 mmol) of corticosterone and 4 Å 
molecular sieves was pumped/purged with N2/vac, then 17 ml of CH2Cl2 was added to the 
mixture.  The mixture was stirred at room temperature for 10 min then placed on an ice bath.  
0.11 ml (0.87 mmol) of BF3·OEt2 was added to the mixture at 0 ˚C, then the reaction was stirred 
at room temperature for 5 h. The reaction was filtered, diluted with hexanes, and washed with 
saturated NaHCO3 (3 x 3 ml).  The organic portion was dried over Mg2SO4 and evaporated to a 
tan foam which was purified by column chromatography in 1:1 Hex/EtOAc (Rf = 0.28, stained 
in CAM) to isolate compound 35 as a white solid.  The NMR data of 35 matched that reported by 
Ciuffreda et al.35
                                                 
35 Ciuffreda, P., Casati, S., De Mieri, M., Ferraboshi, P.  Steroids, 2009, 74, 870 – 875. 
 with one discrepancy in the 13C data.  Ciuffreda at al. reported a resonance at 
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54.70 ppm, whereas we observerved this resonance at 57.68 ppm. 1H NMR (500 MHz, CDCl3):  
NMR δ 5.65 (1 H, d, J = 10 Hz), 5.22 (2 H, dt, J = 30.4 Hz), 5.03 (1 H, dd, J = 7.7, 9.2 Hz), 4.74 
(1 H, d, J = 7.7 Hz), 4.44 (1, m), 4.35 (2 H, d, J = 17.2 Hz), 4.17 (1 H, d, J = 17.2), 4.09 (1 H, q, J 
= 7 Hz), 3.99 (1 H, J = 9.7 Hz), 3.72 (3 H, s), 2.47 (3 H, m), 2.34 (1 H, dt, J = 4, 16.7 Hz), 2.25 – 
2.15 (3 H, m), 2.02 (3 H, s), 2.00 (3 H, s), 1.99 (3 H, s), 1.85 (1 H, td, J = 4.6, 13.6 ), 1.77 – 1.71 
(1 H, m), 1.64 – 1.57 (3 H, m), 1.38 – 1.31 (1 H, m), 1.13 – 1.03 (2 H, m), 0.97 (1 H, dd, J = 2.9 
11, Hz).  13C (75 MHz, CDCl3):  NMR δ 206.45, 199.52, 171.97, 169.92, 169.53, 169.37, 167.43 
122.38, 98.93, 72.54, 72.15, 71.74, 70.72, 69.27, 67.97, 58.9, 57.68, 53.15, 47.84, 43.82, 39.24, 
34.89, 33.84, 32.61, 32.01, 31.5, 24.53, 22.08, 20.81, 20.73, 20.58, 20.46, 16.25.   
 
 
Corticosterone-glucuronide (36)35: 
 
 
 
 
 
 0.17 g (0.25 mmol) of 35 in 4.2 ml of MeOH was treated slowly with 8.4 ml of about a 1 
% sodium hydroxide solution in MeOH (about 8 equivalents of NaOH) over 10 min.  The 
mixture was allowed to stir at room temperature for 24 h.  Dowex 50W-X8 was added to reach 
pH 3.5 – 4.  The suspension was filtered through celite, and the filtrate was concentrated to a 
foam which was purified by column chromatography in 95:4:1 EtOAc/MeOH/H2O (Rf = 0.25, 
stained in CAM) to isolate 12 mg (10 %) of pure 36 as a white solid.  The NMR data of 36 
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matched closely which those of the reported 36; however the 13C data reported here are shifted 
0.50 ppm upfield of the reported 13C data35 presumably due to a referencing error in the original 
paper.  Here, the central peak of DMSO-d6 (2.50 ppm for 1H, and 39.5 ppm for 13C) signals were 
used as an internal reference standard. 1H NMR (500 MHz, CDCl3):  NMR δ 5.56 (1 H, s), 5.21 
(1 H, d, J = 4.7 Hz), 5.11 (1 H, d, J = 5 Hz), 4.33 (1 H broad d, J = 1.5 Hz), 4.27 (2 H, dd, J = 
4.7, 12.5 Hz), 4.23 – 4.17 (2 H, m), 3.55 (1 H, d, J = 9.7 Hz), 3.28 (1 H, t, J = 9.3 Hz), 3.15 (1 H, 
td, J = 4.3, 8.8 Hz), 3.04 (1 H, m), 2.68 (1 H, t, J = 9 Hz), 2.44 – 2.35 (2 H, m), 2.20 – 2.02 (5 H, 
m), 1.92 – 1.52 (5 H, m), 1.36 (3 H, s), 1.25 – 0.89 (5 H, m), 0.79 (3 H, s). 13C (75 MHz, CDCl3):  
NMR δ 207.27, 198.04, 172.27, 170.47, 121.49, 102.37, 76, 75.46, 73.64, 73.09, 71.48, 66.23, 
58.03, 56.88, 55.47, 46.39, 43.35, 38.83, 34.01, 33.46, 32.47, 31.3, 31.09, 24.09, 21.73, 20.34, 
15.67.     
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